News | January 07, 2025
Japan Health Authority approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara
The biosimilar Ustekinumab has been developed and manufactured by the company
The biosimilar Ustekinumab has been developed and manufactured by the company
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
For people with relapsed or refractory diffuse large B-cell lymphoma
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Subscribe To Our Newsletter & Stay Updated
